Search research articles
Contact Us
Filters
Showing results (11-20 of 57) with videos related to
Page
of 6
Sort By:
Harefuah
|
May 17, 2011
[Why do good drugs disappear?]
Mayer Brezis, Ron Tomer, Samuel Klang, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 21, 2021
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus
Ariel Hammerman, Joseph Azuri, Enis Aboalhasan, et al.
International Journal of Cardiology
|
July 9, 2016
PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
Ronen Arbel, Ariel Hammerman, Noa Triki, et al.
Clinical Drug Investigation
|
May 26, 2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Clinical Drug Investigation
|
June 8, 2020
Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Harefuah
|
December 15, 2011
[Public financing for off-label use of drugs]
Ariel Hammerman, Yoel Lipschitz, Joseph Pliskin, et al.
Diabetes, Obesity & Metabolism
|
December 12, 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Obesity (Silver Spring, Md.)
|
May 19, 2023
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Plos One
|
September 17, 2015
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
Ariel Hammerman, Sari Greenberg-Dotan, Ilan Feldhamer, et al.
Postgraduate Medicine
|
June 15, 2022
Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6
Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 57) with videos related to
Sort By:
Page
of 6
Harefuah
|
May 17, 2011
[Why do good drugs disappear?]
Mayer Brezis, Ron Tomer, Samuel Klang, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
October 21, 2021
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus
Ariel Hammerman, Joseph Azuri, Enis Aboalhasan, et al.
International Journal of Cardiology
|
July 9, 2016
PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
Ronen Arbel, Ariel Hammerman, Noa Triki, et al.
Clinical Drug Investigation
|
May 26, 2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Clinical Drug Investigation
|
June 8, 2020
Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis
Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Harefuah
|
December 15, 2011
[Public financing for off-label use of drugs]
Ariel Hammerman, Yoel Lipschitz, Joseph Pliskin, et al.
Diabetes, Obesity & Metabolism
|
December 12, 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Obesity (Silver Spring, Md.)
|
May 19, 2023
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Plos One
|
September 17, 2015
Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
Ariel Hammerman, Sari Greenberg-Dotan, Ilan Feldhamer, et al.
Postgraduate Medicine
|
June 15, 2022
Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6
Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, et al.
Page
of 6